Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1996-01-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM950642APMID 8568812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis of aldehydic peptides inhibiting renin.

  2009cited by this paper
• A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing (*)

  1995cited by this paper
• Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase.

  1995cited by this paper
• Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.

  1995cited by this paper
• Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.

  1994cited by this paper
• Pseudopeptide inhibitors of Ras farnesyl-protein transferase.

  1994cited by this paper
• Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

  1993cited by this paper
• Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.

  1993cited by this paper
• Posttranslational processing of the ras superfamily of small GTP-binding proteins.

  1993cited by this paper
• Protein prenylation: genes, enzymes, targets, and functions.

  1992cited by this paper
• Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein

  1992cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

  1992cited by this paper
• Ras C-terminal processing enzymes--new drug targets?

  1991cited by this paper
• Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase.

  1991cited by this paper
• Identification and preliminary characterization of protein-cysteine farnesyltransferase.

  1990cited by this paper
• Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.

  1990cited by this paper
• All ras proteins are polyisoprenylated but only some are palmitoylated.

  1989cited by this paper
• Post‐translational processing of p21ras is two‐step and involves carboxyl‐methylation and carboxy‐terminal proteolysis.

  1989cited by this paper
• Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas.

  1988cited by this paper
• ras genes.

  1987cited by this paper
• Expression of p21 proteins in Escherichia coli and stereochemistry of the nucleotide‐binding site.

  1986cited by this paper
• Biochemical properties of a highly purified v-rasH p21 protein overproduced in Escherichia coli and inhibition of its activities by a monoclonal antibody

  1985cited by this paper
• 2-Aminoindan-2-carboxylic acids. Potential tyrosine hydroxylase inhibitors.

  1971cited by this paper

• Tropone-Enabled Pd-Catalyzed C(sp2)-H Functionalization of Phenylalanine: Switchable Access to Indoline and Olefinate.

  2025cites this paper
• Site-Selective Modification of Peptides via Late-Stage Pd-Catalyzed Tandem Reaction of Phenylalanine with Benzoquinone.

  2023cites this paper
• Highly Efficient Synthesis of Indoline Via Palladium Catalyzed C-H Amination of C(Sp2)-H Bond Using Tert-Butyl Peroxybenzoate as an Oxidant

  2022cites this paper
• New approaches towards the synthesis of 1,2,3,4-tetrahydro isoquinoline-3-phosphonic acid (TicP)

  2021cites this paper
• Antagonizing S1P3 Receptor with Cell-Penetrating Pepducins in Skeletal Muscle Fibrosis

  2021cites this paper
• Amino sulfonic acids, peptidosulfonamides and other related compounds

  2018cites this paper
• Pd-catalyzed intramolecular C(sp2)-H amination of phenylalanine moieties in dipeptides: synthesis of indoline-2-carboxylate-containing dipeptides.

  2018cites this paper
• Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.

  2016cites this paper
• Assembly of indoline-2-carboxylate-embodied dipeptides via Pd-catalyzed C(sp2)-H bond direct functionalization.

  2015cites this paper
• Allylic Amines as Key Building Blocks in the Synthesis of (E)-Alkene Peptide Isosteres.

  2012cites this paper
• treatment for hematologic malignancies? Targeting the Ras signaling pathway: a rational, mechanism-based

  2011cites this paper
• Further studies toward the stereocontrolled synthesis of silicon-containing peptide mimics.

  2010cites this paper
• Applications and modifications of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in peptides and peptidomimetics design and discovery.

  2010cites this paper
• Conformational preferences of proline analogues with a fused benzene ring.

  2010cites this paper
• Peptide-Like Molecules (PLMs): A Journey from Peptide Bond Isosteres to Gramicidin S Mimetics and Mitochondrial Targeting Agents.

  2009cites this paper
• Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease

  2009cites this paper
• Molecular events as targets of anticancer drug therapy

  2008cites this paper
• The role of RalA and RalB in cancer

  2008cites this paper
• Stereocontrolled synthesis of methyl silanediol peptide mimics.

  2007cites this paper
• Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth

  2007cites this paper
• Cellular Mechanism of Arglabin-Dimethylaminohydrochloride Cytotoxicity

  2006cites this paper
• Convergent approach to (E)-alkene and cyclopropane peptide isosteres.

  2005cites this paper
• Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network.

  2004cites this paper
• Design, synthesis, and evaluation of sugar amino acid based inhibitors of protein prenyl transferases PFT and PGGT-1.

  2004cites this paper
• RAS Inhibitors in Hematologic Cancers: Biologic Considerations and Clinical Applications

  2004cites this paper
• Solid-phase intramolecular N-acyliminium Pictet-Spengler reactions as crossroads to scaffold diversity.

  2004cites this paper
• ras Oncogene Inhibitors

  2004cites this paper
• Farnesyltransferase inhibitors: recent advances

  2004cites this paper
• The Pictet-Spengler reaction in solid-phase combinatorial chemistry.

  2003cites this paper
• Studies on the viability of cyclopropane-containing peptidomimetics and application of the vinylogous Mannich reaction to the syntheses of indolizidine natural products

  2003cites this paper
• Efficient synthesis of 2-aminoindane-2-carboxylic acid via dialkylation of nucleophilic glycine equivalent.

  2003cites this paper
• Molecular modeling in the design of peptidomimetics and peptide surrogates.

  2002cites this paper
• Protein farnesyltransferase inhibitors.

  2002cites this paper
• Specific cell-signal targets for cancer chemotherapy

  2002cites this paper
• Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.

  2002cites this paper
• Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells.

  2001cites this paper
• Antitumor Efficacy of a Farnesyltransferase Inhibitor in Transgenic Mice

  2001cites this paper
• Cyclopropane-derived peptidomimetics. design, synthesis, and evaluation of novel Ras farnesyltransferase inhibitors.

  2001cites this paper
• Phospholipase D Activation by Norepinephrine Is Mediated by 12(S)-, 15(S)-, and 20-Hydroxyeicosatetraenoic Acids Generated by Stimulation of Cytosolic Phospholipase A2

  2001cites this paper
• Farnesyltransferase Inhibitors in Cancer Therapy

  2001cites this paper
• From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase

  2001cites this paper
• by a Farnesyl : Protein Transferase Inhibitor Develop Mammary Carcinomas That Can Be Growth-inhibited B Transgenic Mice ras Mouse Mammary Tumor Virus-Ki-Updated

  2000cites this paper
• The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases

  2000influential citation
• Ras – ein molekularer Schalter bei der Tumorentstehung

  2000cites this paper
• Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

  2000cites this paper
• Ras-A Molecular Switch Involved in Tumor Formation.

  2000cites this paper
• Ras-Farnesyltransferase-Inhibitors as Promising Anti-Tumor Drugs

  2000cites this paper
• Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.

  2000cites this paper
• Farnesyltransferase and Geranylgeranyltransferase Inhibitors

  2000cites this paper
• Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

  2000cites this paper
• Assessment of the bioactive conformation of the farnesyltransferase protein binding recognition motif by computational methods.

  1999cites this paper
• Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase.

  1999cites this paper
• Synthesis and biological activity of pseudopeptides inhibitors of Ras farnesyl transferase containing unconventional amino acids.

  1999cites this paper
• Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.

  1999cites this paper
• XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase.

  1999cites this paper
• Alpha-cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of Ras farnesylation.

  1999cites this paper
• Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.

  1999cites this paper
• Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors.

  1999cites this paper
• Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.

  1999cites this paper
• Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

  1999cites this paper
• beta-hexosaminidase-induced activation of p44/42 mitogen-activated protein kinase is dependent on p21Ras and protein kinase C and mediates bovine airway smooth-muscle proliferation.

  1999cites this paper
• Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase.

  1999cites this paper
• Farnesyl transferase inhibitors: Design of a new class of cancer chemotherapeutic agents

  1999cites this paper
• Towards control of χ-space: Conformationally constrained analogues of Phe, Tyr, Trp and His

  1999cites this paper
• Inhibiteurs de la farnesyle transferase

  1999cites this paper
• New approaches to anticancer drug design based on the inhibition of farnesyltransferase

  1998cites this paper
• Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation.

  1998cites this paper
• Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.

  1998cites this paper
• Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target.

  1998cites this paper
• (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.

  1998cites this paper
• Phenol-derived CVFM analog inhibitors of Ras Farnesyltransferase possessing cellular in vitro activity 1

  1998cites this paper
• HEMMSTOFFE DER FARNESYLTRANSFERASE: EIN NEUER ANSATZ ZUR ENTWICKLUNG POTENTIELLER KREBSTHERAPEUTIKA

  1998cites this paper
• 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells.

  1998cites this paper
• [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].

  1998cites this paper
• Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

  1998cites this paper
• CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.

  1997cites this paper
• [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].

  1997cites this paper
• Synthesis of characteristic lipopeptides of the human N-Ras protein and their evaluation as possible inhibitors of protein farnesyl transferase.

  1997cites this paper
• Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.

  1997cites this paper
• Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors.

  1997cites this paper
• Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.

  1997cites this paper
• Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.

  1997cites this paper
• C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

  1997cites this paper
• Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.

  1997cites this paper
• Substrate specificity determinants in the farnesyltransferase beta-subunit.

  1997cites this paper
• Synthesis of triphosphonate analogues of farnesyl pyrophosphate. Inhibitors of squalene synthase and protein:farnesyl transferase

  1997cites this paper
• Ras farnesyltransferase: a new therapeutic target.

  1997cites this paper
• Enzymatic Synthesis of Peptide Conjugates: Tools for the Study of Biological Signal Transduction

  1997cites this paper
• Farnesyltransferase as a target for anticancer drug design.

  1997cites this paper
• Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase.

  1997cites this paper
• Cholesterol metabolism and tumor cell proliferation.

  1997cites this paper
• RAS and the myelodysplastic syndromes.

  1997cites this paper
• The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

  1997cites this paper
• Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

  1997cites this paper
• Chapter 18. Ras Farnesyltransferase Inhibitors

  1996cites this paper
• Identification of isoprenyl modified proteins metabolically labeled with [3H]farnesyl‐ and [3H]geranylgeranyl‐pyrophosphate

  1996cites this paper
• Patent Update Oncologic, Endocrine & Metabolic: Oncologic, Endocrine & Metabolic: Inhibitors of protein farnesylation

  1996cites this paper
• Inhibitors of the Ras signal transduction pathway as potential antitumour agents.

  1996cites this paper